Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T72245
|
||||
| Former ID |
TTDR00277
|
||||
| Target Name |
Alpha v beta 3 integrin receptor
|
||||
| Gene Name |
ITGB3
|
||||
| Synonyms |
Alpha v beta 3 integrin; Alpha(v)beta(3) Integrin; Alpha(v)beta(3) integrin receptor; Integrin alpha V beta 3; Integrin alpha-v beta-3; Integrin alphaVbeta3; Vitronectin Receptor; ITGB3
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Cancer [ICD9: 140-229; ICD10: C00-C96] | ||||
| Peripheral vascular disease [ICD9: 443.9; ICD10: I73.9] | |||||
| BioChemical Class |
Integrin
|
||||
| UniProt ID | |||||
| Sequence |
MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLG
SPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRP DDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFG AFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSR NRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCH VGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLS MDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDT VSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGT FECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFG KITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLL CSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRY CRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDIL VVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTF TNITYRGT |
||||
| Structure |
1JV2; 1L5G; 1M1X; 1U8C; 3IJE; 4G1E; 4G1M; 4MMX; 4MMY; 4MMZ; 4O02; 4UM8; 4UM9
|
||||
| Drugs and Mode of Action | |||||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| Reactome | Platelet degranulation | ||||
| Cross-presentation of particulate exogenous antigens (phagosomes) | |||||
| Elastic fibre formation | |||||
| PECAM1 interactions | |||||
| Molecules associated with elastic fibres | |||||
| Integrin cell surface interactions | |||||
| Laminin interactions | |||||
| Syndecan interactions | |||||
| ECM proteoglycans | |||||
| Integrin alphaIIb beta3 signaling | |||||
| SOS provides linkage to MAPK signaling for Integrins | |||||
| p130Cas linkage to MAPK signaling for integrins | |||||
| VEGFA-VEGFR2 Pathway | |||||
| MAP2K and MAPK activation | |||||
| WikiPathways | Osteoblast Signaling | ||||
| Focal Adhesion | |||||
| Class I MHC mediated antigen processing & | |||||
| presentation | |||||
| Syndecan interactions | |||||
| Extracellular matrix organization | |||||
| Elastic fibre formation | |||||
| Primary Focal Segmental Glomerulosclerosis FSGS | |||||
| Arrhythmogenic Right Ventricular Cardiomyopathy | |||||
| Integrin-mediated Cell Adhesion | |||||
| L1CAM interactions | |||||
| Integrin cell surface interactions | |||||
| Cell surface interactions at the vascular wall | |||||
| Osteopontin Signaling | |||||
| References | |||||
| Ref 532373 | Synthesis of [18F]RGD-K5 by catalyzed [3 + 2] cycloaddition for imaging integrin alphavbeta3 expression in vivo. Nucl Med Biol. 2013 Jul;40(5):710-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.